SPY412.86+1.22 0.30%
DIA336.79-0.76 -0.23%
IXIC13,996.10+146.10 1.05%

Aprea Therapeutics: Believes Its Cash and Cash Equivalents as of Dec 31, 2020 Will Be Sufficient to Meet Its Current Projected Operating Requirements Into 2023 >APRE

Aprea Therapeutics: Believes Its Cash and Cash Equivalents as of Dec 31, 2020 Will Be Sufficient to Meet Its Current Projected Operating Requirements Into 2023 >APRE

· 03/16/2021 16:17

Please log in to view news